Broad-spectrum antiviral activity of 3D8, a nucleic acid-hydrolyzing single chain variable fragment (scFv), targeting SARS-CoV-2 and multiple coronaviruses in vitro
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
The current pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the etiology of Coronavirus-induced disease 19 (COVID-19) and poses a critical public health threat worldwide. Effective therapeutics and vaccines against multiple coronaviruses remain unavailable. Single chain variable fragment (scFv), a recombinant antibody exhibits broad-spectrum antiviral activity against DNA and RNA viruses owing to its nucleic acid-hydrolyzing property.
Objective
This study is aimed to investigate an antiviral activity of 3D8 scFv against SARS-CoV-2 and other coronaviruses.
Methods
3D8, a recombinant scFv antibody was evaluated for antiviral activity against SARS-CoV-2, HCoV-OC43 and PEDV in Vero E6 cell cultures. Viral growth was quantified with quantitative RT-qPCR and plaque assay. Nucleic acid hydrolyzing activity of 3D8 was assessed through abzyme assays of in vitro viral transcripts and cell viability was determined by MTT assay.
Results
3D8 inhibited the replication of SARS-CoV-2, human coronavirus OC43 (HCoV-OC43), and porcine epidemic diarrhea virus (PEDV). Our results revealed the prophylactic and therapeutic effects of 3D8 scFv against SARS-CoV-2 in Vero E6 cells. Immunoblot and plaque assays showed the reduction of coronavirus nucleoproteins and infectious particles respectively in 3D8 scFv-treated cells.
Conclusions
This data demonstrates the broad-spectrum antiviral activity of 3D8 against SARS-CoV-2 and other coronaviruses. Thus, it could be considered a potential antiviral countermeasure against SARS-CoV-2 and zoonotic coronaviruses.
Article activity feed
-
-
SciScore for 10.1101/2020.11.25.398909: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After transmembrane transfer, it was incubated with primary antibodies; anti-SARS-CoV-2 (PA1-41098, Invitrogen, Thermo Fisher Scientific, Massachusetts, USA) anti-SARS-CoV-2 ( PA1-41098suggested: None, anti-PEDV (9191, Median Diagnostics, Chuncheon-si, ROK), anti-HCoV-OC43(LS-C79764, LS-bio, Seattle, WA, USA) and anti-human GAPDH antibody (ab9485, Abcam, Cambridge, UK) overnight at 4°C and then incubated with anti-mouse or rabbit IgG-HRP conjugate … SciScore for 10.1101/2020.11.25.398909: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources After transmembrane transfer, it was incubated with primary antibodies; anti-SARS-CoV-2 (PA1-41098, Invitrogen, Thermo Fisher Scientific, Massachusetts, USA) anti-SARS-CoV-2 ( PA1-41098suggested: None, anti-PEDV (9191, Median Diagnostics, Chuncheon-si, ROK), anti-HCoV-OC43(LS-C79764, LS-bio, Seattle, WA, USA) and anti-human GAPDH antibody (ab9485, Abcam, Cambridge, UK) overnight at 4°C and then incubated with anti-mouse or rabbit IgG-HRP conjugate (209-035-082 or 309-035-003, Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at 37 °C. anti-PEDVsuggested: Noneanti-human GAPDHsuggested: Noneanti-mousesuggested: Nonerabbit IgG-HRPsuggested: NoneAfter blocking with 1% BSA and 0.3 M (22.52 mg/ml) glycine in PBST buffer for 1 h at room temperature, primary antibodies for detecting PEDV (mouse anti-PEDV monoclonal Ab, MBS313516, Mybio), HCoV-OC43 (mouse anti-OC43 monoclonal Ab, LS-C79764, LS-bio) and 3D8 (polyclonal rabbit IgG serum Ab) were incubated overnight at 4 °C. HCoV-OC43suggested: Noneanti-OC43suggested: NoneExperimental Models: Cell Lines Sentences Resources Cells and viruses: African green monkey kidney epithelial Vero cells (ATCC® CCL-81) and Vero E6 cells (ATCC® CRL-1586) were maintained in Dulbecco’s modified Eagle’s medium (12-604F, Lonza, BioWhittaker®, Walkersville, MD, USA) supplemented with 10% Fetal bovine serum (FBS, Gibco, Life Technologies, Grand Island, NY, USA), 1% 10 mM HEPES in 0.85% NaCl (17-737E, Lonza, BioWhittaker®, Walkersville, MD, USA) and 100 U/ml Penicillin-100 µg/ml Streptomycin (15140-122, Gibco, Life Technologies, Grand Island, NY, USA) Verosuggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)In case of prophylactic treatment, Vero E6 cells were treated with 3D8 and incubated overnight before the virus challenge. Vero E6suggested: NoneSoftware and Algorithms Sentences Resources Viral RNA was quantified using Power SYBR® Green PCR Master Mix (4367659, Applied Biosystems™, Life Technologies Ltd., Woolston Applied Biosystems™suggested: (Applied Biosystems, RRID:SCR_005039)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, the absence of in vivo studies in animal models is a major limitation. To address this issue, further studies are needed to illustrate the in vivo inhibitory effect of 3D8 scFv in transgenic mice, Syrian hamsters and non-human primate models. In conclusion, 3D8 scFv confers broad-spectrum antiviral activity against SARS-CoV-2 and multiple coronaviruses. This study provides insights into the effective antiviral countermeasure of scFv against emerging viral outbreaks.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-